Skip to main content
Midas Edge

NRX Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 14, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 14, 2025

NRXP$2.380.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Part I

Unless the context requires otherwise, references in this annual report to“NRx,”* “Company,” “we,” “us” and*“our”* and similar designations refer to NRx Pharmaceuticals, Inc. and its subsidiaries.*

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.